These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 27513321)

  • 1. Qualification of computerized monitoring systems in a cell therapy facility compliant with the good manufacturing practices.
    Del Mazo-Barbara A; Mirabel C; Nieto V; Reyes B; García-López J; Oliver-Vila I; Vives J
    Regen Med; 2016 Sep; 11(6):521-8. PubMed ID: 27513321
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Qualification of academic facilities for small-scale automated manufacture of autologous cell-based products.
    Hourd P; Chandra A; Alvey D; Ginty P; McCall M; Ratcliffe E; Rayment E; Williams DJ
    Regen Med; 2014; 9(6):799-815. PubMed ID: 25431916
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Towards a common framework for defining ancillary material quality across the development spectrum.
    Ball O; Zylberberg C
    Cytotherapy; 2019 Dec; 21(12):1234-1245. PubMed ID: 31837736
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aid conditionalities, international Good Manufacturing Practice standards and local production rights: a case study of local production in Nepal.
    Brhlikova P; Harper I; Subedi M; Bhattarai S; Rawal N; Pollock AM
    Global Health; 2015 Jun; 11():25. PubMed ID: 26072308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Innovative regenerative medicines in the EU: a better future in evidence?
    Corbett MS; Webster A; Hawkins R; Woolacott N
    BMC Med; 2017 Mar; 15(1):49. PubMed ID: 28270209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Translation of Cell Therapy, Tissue Engineering, and Regenerative Medicine Product in Malaysia and Its Regulatory Policy.
    Bt Hj Idrus R; Abas A; Ab Rahim F; Saim AB
    Tissue Eng Part A; 2015 Dec; 21(23-24):2812-6. PubMed ID: 26192075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality Risk Management: Putting GMP Controls First.
    O'Donnell K; Greene A; Zwitkovits M; Calnan N
    PDA J Pharm Sci Technol; 2012; 66(3):243-61. PubMed ID: 22634590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Organ Chips: Quality Assurance Systems in Regenerative Medicine.
    Pasqualini FS; Emmert MY; Parker KK; Hoerstrup SP
    Clin Pharmacol Ther; 2017 Jan; 101(1):31-34. PubMed ID: 27709615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Control systems engineering in continuous pharmaceutical manufacturing. May 20-21, 2014 Continuous Manufacturing Symposium.
    Myerson AS; Krumme M; Nasr M; Thomas H; Braatz RD
    J Pharm Sci; 2015 Mar; 104(3):832-9. PubMed ID: 25546650
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Good Manufacturing Practice for Medicinal Products in Bulgaria: an Analysis of Regulatory Inspection Findings.
    Stoimenova AH; Kirilov BJ; Gueorguiev SR; Petkova-Gueorguieva ES; Ognianov SG
    Folia Med (Plovdiv); 2020 Mar; 62(1):165-171. PubMed ID: 32337904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell and gene therapy manufacturing capabilities in Australia and New Zealand.
    O'Sullivan GM; Velickovic ZM; Keir MW; Macpherson JL; Rasko JEJ
    Cytotherapy; 2019 Dec; 21(12):1258-1273. PubMed ID: 31806531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multiscale simulation framework for the manufacturing facility and supply chain of autologous cell therapies.
    Wang K; Liu Y; Li J; Wang B; Bishop R; White C; Das A; Levine AD; Ho L; Levine BL; Fesnak AD
    Cytotherapy; 2019 Oct; 21(10):1081-1093. PubMed ID: 31445816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Media fill for validation of a good manufacturing practice-compliant cell production process.
    Serra M; Roseti L; Bassi A
    Methods Mol Biol; 2015; 1283():161-9. PubMed ID: 25096172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Concise review: guidance in developing commercializable autologous/patient-specific cell therapy manufacturing.
    Eaker S; Armant M; Brandwein H; Burger S; Campbell A; Carpenito C; Clarke D; Fong T; Karnieli O; Niss K; Van't Hof W; Wagey R
    Stem Cells Transl Med; 2013 Nov; 2(11):871-83. PubMed ID: 24101671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. WHO expert committee on specifications for pharmaceutical preparations. Fortieth report.
    WHO Expert Committee on Specifications for Pharmaceutical Preparations
    World Health Organ Tech Rep Ser; 2006; 937():1-461, back cover. PubMed ID: 16836287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Uncertain Oversight of Regenerative Medicines in Japan under the ASRM.
    Lysaght T; Sugii S
    Cell Stem Cell; 2016 Apr; 18(4):438-9. PubMed ID: 27058936
    [No Abstract]   [Full Text] [Related]  

  • 17. Regulation Policy for Cell and Tissue Therapies in Australia.
    Sturm M
    Tissue Eng Part A; 2015 Dec; 21(23-24):2797-801. PubMed ID: 26096750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of ISO 9002 and FDA's good manufacturing practices to general chemical manufacturing.
    Kauffman JM; Weiler ED
    Qual Assur; 1992 Jun; 1(3):213-6. PubMed ID: 1344676
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Challenges and advantages of cell therapy manufacturing under Good Manufacturing Practices within the hospital setting.
    Iancu EM; Kandalaft LE
    Curr Opin Biotechnol; 2020 Oct; 65():233-241. PubMed ID: 32663771
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Validation of the process control system of an automated large scale manufacturing plant.
    Neuhaus H; Kremers H; Karrer T; Traut RH
    Pharm Acta Helv; 1998 Feb; 72(6):333-42. PubMed ID: 9556434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.